Pliant Therapeutics to Participate in Upcoming April 2024 Investor Events

2024-04-02

临床1期快速通道孤儿药

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following April investor events. 23rd Annual Needham Virtual Healthcare Conference Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a fireside chat on Tuesday, April 9, 2024, at 11:45 a.m. Eastern Time. Piper Sandler Spring Biopharma Symposium Members of Pliant’s senior management will meet with investors on Wednesday, April 17, 2024, as part of an invitation-only event hosted by Piper Sandler. Interested parties may access the live webcast of the Needham fireside chat by visiting the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event. About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, a Phase 2b/3 trial of bexotegrast in IPF. Pliant has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH. Pliant has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition to clinical-stage programs, Pliant currently has a preclinical program targeting muscular dystrophies. For additional information, please visit: Follow us on social media X, LinkedIn, Facebook and YouTube. Investor and Media Contact: Christopher Keenan Vice President, Investor Relations and Corporate Communications Pliant Therapeutics, Inc. ir@pliantrx.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构